Smets L A, Slater R, van Wering E R, van der Does-van den Berg A, Hart A A, Veerman A J, Kamps W A
Division of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Med Pediatr Oncol. 1995 Dec;25(6):437-44. doi: 10.1002/mpo.2950250604.
DNA per cell content was routinely recorded by single-parameter flow cytometry in leukemic blasts from 473 children with acute lymphoblastic leukemia (ALL), enrolled in national studies ALL V, VI, and VII (1979-1991) of the Dutch Childhood Leukemia Study Group. The parameters bonemarrow %S-value and DNA Index were compared with clinical features, with chromosome number based on cytogenetic analyses and with treatment results in study ALL VI. %S-values, ranging between 1 and 36%, were unrelated to initial white blood cell count, immunophenotype, and DNA index but were lowest in blasts with L1 morphology. In study ALL VI (non-high risk), the survival of patients with < or = 6% S-phase cells was superior to that of patients with %S-values of > 6 (P = 0.030). Hyperdiploidy, defined by a DNA index > or = 1.16, was compared to the cytogenetic hyperdiploid classification of n > 50. Initially there were 25 discrepancies in 189 samples jointly analysed by flow cytometry and cytogenetics. After review only five discrepancies remained unresolved. Hyperdiploidy, independent of the method used, was found to be unrelated to blast morphology and %S-phase cells but closely associated with c-ALL and was absent in T-ALL. In study ALL VI, event-free survival at 8 years of hyperdiploid patients was 90.6% but was not significantly different from non-hyperdiploid patients (EFS = 82.1%; P = 0.08). Routine DNA flow cytometry appeared a valuable adjunct to cytogenetic analyses and allowed the identification of a large subset of non-high-risk ALL patients in study ALL VI with a DNA index > or = 1.16 or %S-value of < or = 6.0 with highest survival probability.
荷兰儿童白血病研究组在1979 - 1991年的全国性ALL V、VI和VII研究中,对473例急性淋巴细胞白血病(ALL)患儿的白血病原始细胞,通过单参数流式细胞术常规记录每个细胞的DNA含量。将骨髓%S值和DNA指数参数与临床特征、基于细胞遗传学分析的染色体数目以及ALL VI研究中的治疗结果进行比较。%S值在1%至36%之间,与初始白细胞计数、免疫表型和DNA指数无关,但在L1形态的原始细胞中最低。在ALL VI研究(非高危)中,S期细胞≤6%的患者生存率高于%S值>6%的患者(P = 0.030)。将DNA指数≥1.16定义的超二倍体与细胞遗传学超二倍体分类(n>50)进行比较。最初,在189份同时通过流式细胞术和细胞遗传学分析的样本中有25个差异。复查后仅5个差异仍未解决。发现超二倍体与所用方法无关,与原始细胞形态和%S期细胞无关,但与普通型ALL密切相关,在T-ALL中不存在。在ALL VI研究中,超二倍体患者8年无事件生存率为90.6%,但与非超二倍体患者无显著差异(无事件生存率=82.1%;P = 0.08)。常规DNA流式细胞术似乎是细胞遗传学分析的有价值辅助手段,并且在ALL VI研究中能够识别出DNA指数≥1.16或%S值≤6.0且生存概率最高的一大类非高危ALL患者。